Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

British journal of haematology·2026
Same author

A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same author

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
Same author

NK cell-based immunotherapy.

Human vaccines & immunotherapeutics·2026
Same author

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.

Bone marrow transplantation·2026

Related Experiment Video

Updated: May 13, 2026

Germ Cell Transplantation and Testis Tissue Xenografting in Mice
10:41

Germ Cell Transplantation and Testis Tissue Xenografting in Mice

Published on: February 6, 2012

Transplantation for refractory germ cell tumors: does it really make a difference?

Yago Nieto1

  • 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, 77030, USA. ynieto@mdanderson.org

Current Oncology Reports
|March 16, 2013
PubMed
Summary

High-dose chemotherapy (HDC) shows limited benefit for high-risk germ-cell tumors (GCT) upfront. However, it offers potential cures for a subset of patients with relapsed or refractory GCT.

More Related Videos

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

Related Experiment Videos

Last Updated: May 13, 2026

Germ Cell Transplantation and Testis Tissue Xenografting in Mice
10:41

Germ Cell Transplantation and Testis Tissue Xenografting in Mice

Published on: February 6, 2012

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

Area of Science:

  • Oncology
  • Medical Treatments

Background:

  • High-dose chemotherapy (HDC) has been utilized for germ-cell tumors (GCT) for 25 years.
  • Current consensus indicates HDC is not beneficial as first-line treatment for high-risk GCT.

Purpose of the Study:

  • To evaluate the efficacy of HDC in managing relapsed or refractory germ-cell tumors.
  • To discuss the ongoing debate surrounding HDC's role in GCT treatment.
  • To highlight the development of prognostic models for patient selection.

Main Methods:

  • Review of long-term results from prospective trials involving patients with relapsed or refractory GCT.
  • Analysis of prognostic models designed to identify patients who may benefit from HDC-based therapies.

Main Results:

  • A fraction of patients with relapsed or refractory GCT achieve long-term remission or cure with HDC.
  • Prognostic models have been developed to identify patients with poor prognosis who might benefit from novel HDC approaches.

Conclusions:

  • HDC is an accepted treatment for relapsed/refractory GCT by many US oncologists, despite controversy.
  • HDC may offer curative potential for a specific subgroup of patients with advanced GCT.
  • Prognostic models are crucial for guiding the application of HDC-based strategies in GCT management.